Add to ORKGThe content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships relevant to the content of this article have been disclosed by the authors or independent peer reviewers. The article discusses sunitinib (Pfizer) for the treatment of medullary thyroid carcinoma. Context. Medullary thyroid carcinoma (MTC) is a neu-roendocrine tumor arising from “C ” cells of the thy-roid; it is a RET associated cancer that can be sporadic or familial in origin. Advances in understanding the ge-netic changes associated with the development of MTC explain the growing interest in the therapeutic potential of tyrosine kinase inhibitors. Sunitinib is an o...
The article in this issue by Faivre et al1 describing a phase I trial of sunitinib is an important c...
Background: Management of medullary thyroid carcinoma (MTC) remains controversial despite many advan...
Medullary thyroid cancer (MTC) is a rare disorder that accounts for approximately 1.7 % of all thyro...
The article discusses sunitinib (Pfizer) for the treatment of medullary thyroid carcinoma. The conte...
The content of this article has been reviewed by independent peer reviewers to ensure that it is bal...
Background: Sunitinib (SU11248) is an oral multi-target tyrosine kinase inhibitor (TKI) with low mol...
Copyright © 2013 Serena Giunti et al. This is an open access article distributed under the Creative ...
Purpose: Patients with advanced radioactive iodine resistant differentiated (MDTC) or medullary (MMT...
Context: Sunitinib (sunitinib malate; SU11248; Sutent; Pfizer Inc., New York, NY) is a multitarget i...
Background: The multitargeted tyrosine kinase inhibitor sunitinib is known to induce thyroid dysfunc...
Disclosures of potential conflicts of interest may be found at the end of this article. Key Words. T...
Tyrosine kinase receptors play an important role in tumor angiogenesis and, their implication in epi...
Tyrosine kinase receptors play an important role in tumor angiogenesis and, their implication in epi...
Background: Anaplastic thyroid cancer (ATC), while rare, carries a uniformly poor prognosis. Current...
Introduction: Until recently, no therapeutic options were available for the treatment of advanced me...
The article in this issue by Faivre et al1 describing a phase I trial of sunitinib is an important c...
Background: Management of medullary thyroid carcinoma (MTC) remains controversial despite many advan...
Medullary thyroid cancer (MTC) is a rare disorder that accounts for approximately 1.7 % of all thyro...
The article discusses sunitinib (Pfizer) for the treatment of medullary thyroid carcinoma. The conte...
The content of this article has been reviewed by independent peer reviewers to ensure that it is bal...
Background: Sunitinib (SU11248) is an oral multi-target tyrosine kinase inhibitor (TKI) with low mol...
Copyright © 2013 Serena Giunti et al. This is an open access article distributed under the Creative ...
Purpose: Patients with advanced radioactive iodine resistant differentiated (MDTC) or medullary (MMT...
Context: Sunitinib (sunitinib malate; SU11248; Sutent; Pfizer Inc., New York, NY) is a multitarget i...
Background: The multitargeted tyrosine kinase inhibitor sunitinib is known to induce thyroid dysfunc...
Disclosures of potential conflicts of interest may be found at the end of this article. Key Words. T...
Tyrosine kinase receptors play an important role in tumor angiogenesis and, their implication in epi...
Tyrosine kinase receptors play an important role in tumor angiogenesis and, their implication in epi...
Background: Anaplastic thyroid cancer (ATC), while rare, carries a uniformly poor prognosis. Current...
Introduction: Until recently, no therapeutic options were available for the treatment of advanced me...
The article in this issue by Faivre et al1 describing a phase I trial of sunitinib is an important c...
Background: Management of medullary thyroid carcinoma (MTC) remains controversial despite many advan...
Medullary thyroid cancer (MTC) is a rare disorder that accounts for approximately 1.7 % of all thyro...